Compare Aegon Ltd. (AEG) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs Alnylam Pharmaceuticals, Inc. — how do they compare? Aegon Ltd. trades at $9.42 (market cap $14.01B), while Alnylam Pharmaceuticals, Inc. trades at $223.77 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2.1× Aegon Ltd.'s market cap, and Aegon Ltd. pays a 4.94% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| AEG | ALNY | |
|---|---|---|
Market Cap | $14.01B | $29.60B |
Sector | Financials | Health |
52-Week High | $9.53 | $491.22 |
52-Week Low | $6.79 | $205.48 |
Enterprise Value | $15.16B | $27.56B |
Dividend Yield | 4.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.41, down 0.48% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $19.5B in 2024 to $26.9B in 2025 and net income increasing to $977M. Recent strategic moves include relocating to Delaware and simplifying governance while maintaining a dividend payout. Analyst consensus is mixed with 28% buy ratings but 50% hold recommendations.
AEG presents a turnaround story with improving profitability and strategic refocusing on US markets. Key opportunities include continued earnings growth and potential buybacks, while risks involve execution of the US transition and maintaining momentum amid volatile cash flow patterns. The stock offers value with a P/E of 13.5 and P/S of 0.57.
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
